ICER: Madrigal’s Resmetirom Looks More Cost-Effective In NASH Than Intercept’s OCA
Executive Summary
In a draft assessment, the non-profit said Madrigal’s non-alcoholic steatohepatitis candidate might yield cost savings over a lifetime of care. Both drugs seem to offer incremental benefits for survival and quality of life.
You may also be interested in...
Intercept, Madrigal Get Ready For NASH Commercialization
With a 22 June US FDA action date for obeticholic acid in non-alcoholic steatohepatitis, Intercept is thinking ahead to launch plans. Madrigal said it plans a Q2 filing for its NASH drug and hopes to find an ex-US commercial partner.
Intercept Gifts Shareholders With NASH Refiling
Nearly two-and-a-half years after an FDA complete response letter stalled obeticholic acid’s path to the first approval in non-alcoholic steatohepatitis, Intercept refiled its NDA on 23 December.
Madrigal Phase III Success In NASH Spurs Buyout Speculation
With resmetirom hitting its co-primary endpoints, Madrigal intends to file the THRβ agonist for approval during H1 2023 in the liver disease, an unmet medical need with blockbuster earnings potential.